Therefore, we screened eight clinically relevant c-MET inhibitors (foretinib, crizotinib, Pha665752, INCB28060, AMG208, AMG337, EMD1214063, and XL184) in three different HNSCC cell lines (FaDu, SAS, and Cal33) within a dose range of 1–100 μM for different time points (24 h, 48 h, and 72 h) and in combination with 4 Gy irradiation using cell viability assay (CellTiterGlo) (Figure 5A). This evidence concerns the gene MET and head and neck squamous cell carcinoma.